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Abstract
The most common and aggressive brain tumor in the adult population is glioblastoma (GBM). The lifespan of patients
does not exceed 22 months. One of the reasons for the low effectiveness of GBM treatment is its radioresistance and
chemoresistance. In the current review, we discuss the phenomenon of multidrug resistance of GBM in the context of the
expression of ABC family transporter proteins and the mechanisms of proliferation, angiogenesis, and recurrence. We
focused on the search of molecular targets among growth factors, receptors, signal transduction proteins, microRNAs,
transcription factors, proto-oncogenes, tumor suppressor genes, and their single-nucleotide polymorphisms.
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1. Background

G

lioblastoma (GBM) is the most common highgrade, chemoresistant and radioresistant
brain tumor in the adult population [1]. A life expectancy of patients averages 22.3 months, while
100% have relapses [2]. Malignant tumors, which
include GBM, consist of cell populations with
different sensitivity to drugs as a result of the therapy undergoing a clonal selection to increase radioresistance and chemoresistance. When such a
scenario is realized, a tumor recurs, containing
radioresistant and chemoresistant cells. Multidrug
resistance (MDR) of tumors is based on the dysregulation of physiological, pathological, and genetic
processes that regulate the expression of target
genes, tumor suppressors, and proto-oncogenes.
These processes involve molecules such as growth
factors, cytokines, receptors, signaling pathway

molecules, and microRNAs. By contrast, arising
changes in DNA and single-nucleotide polymorphism (SNP) contribute to the translation of
altered proteins in cells. In this review, we highlight
the relationship between proliferation, angiogenesis, metastasis, recurrence, as well as mutations
and SNPs in oncogenes and tumor suppressor
genes in MDR of GBM.

2. Drug resistance mechanisms
2.1. Drug resistance and transporter proteins of the
ABC family
Protein transporters of the ATP-binding cassette
(ABC) family of drugs play a key role in the development of MDR. In humans, 49 genes were identiﬁed that encode proteins of ATP-binding
transporters, which are divided into seven
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subfamilies: ABCA, ABCB, ABCC, ABCD, ABCE,
ABCF, and ABCG [3]. Most of the genes and proteins
involved in MDR of GBM belong to the ABCB,
ABCC, and ABCG subfamilies. Of the ABCB family,
the most well-studied is ABCB1 (ATP binding
cassette subfamily B member 1) protein (P-gp, Pglycoprotein), which is expressed on endothelial
cells of the bloodebrain barrier (BBB) capillaries
and glioma stem cells [4]. P-gp is involved in plasma
and cerebrospinal ﬂuid excretion of anticancer
drugs, organic cations, carbohydrates, oligosaccharides, proteins, and antibiotics [4]. The variety of
substrates of P-gp indicates its participation in the
protection from toxins of tumor stem cells. The
expression of the ABCB1 gene is regulated by transcription factors: p53 (tumor protein p53), NF-kB
(nuclear factor kappa B subunit), AP-1 (K-box region
and MADS-box transcription factor family protein),
EZH2 (enhancer of zeste 2 polycomb repressive
complex 2 subunit), c-Jun/JNK (c-Jun N-terminal
kinase) and signaling pathway kinases: PI3K/AKT
(phosphatidylinositol-4,5-bisphosphate
3-kinase/
serine/threonine-speciﬁc protein kinase 1), GSK-3b
(glycogen synthase kinase 3 beta)/b-catenin, MAPK/
Ras (mitogen-activated protein kinase/small Gprotein)/ERK1/2 (extracellular signal-regulated kinase 1), and p38MAPK (p38 map kinase) [5,6].
MAPK/ERK1/2 kinase pathway is involved in cell
survival, proliferation, and motility, which increases
the activity of P-gp, whereas the p38MAPK
pathway, which activates cell differentiation and
apoptosis, decreases the activity of P-gp [7,8]. It is
well known that the activation of the PI3K/AKT/NFkB pathway facilitates survival, proliferation can
also enhance the expression of the MGMT gene (O6methylguanine-DNA
methyltransferase),
and,
consequently, GBM resistance to temozolomide
(TMZ). Therefore, it is possible that upon activation
of the PI3K/AKT/NF-kB pathway, ABCB1 will
participate in the resistance to TMZ.
In the tumor, stem, and BBB cells, overexpression
of the ABCG2 (ATP binding cassette subfamily G
member 2) gene and breast cancererelated protein
(BCRP) is often observed, enhancing the resistance
of GBM to chemotherapeutic agents: vincristine,
TMZ, topotecan, and irinotecan [9]. Moreover, colocalization of P-gp and BCRP proteins is observed
in GBM and BBB cells, which is associated with their
joint functioning as drug transporters [10]. Moreover, BCRP expression is inhibited through suppression of epidermal growth factor receptor (EGFR)
expression and activation of PERK (eukaryotic
translation initiation factor 2 alpha kinase 3)/ATF4
(activating transcription factor 4)/CHOP (DNA
damage-inducible transcript 3) pathways [11].

2.1.1. MicroRNAs
MicroRNAs (miRNAs, miR) are involved in the
regulation of the transcription of the ABCB1 gene
and protein translation [12]. For example, miR-200c
inhibits the synthesis of P-gp via the JNK signaling
pathway [13]. It is possible that miR-130a can activate ABCB1 expression through PI3K/AKT/PTEN
(phosphatase and tensin homolog)/mTOR (mechanistic target of rapamycin kinase) and Wnt/GSK-3b
(glycogen synthase kinase 3 beta)/b-catenin
signaling pathways [13]. The expression of ABCG2 is
activated by miR-328 and transcription factor EZH2
[14].
2.1.2. Genes ABCB1 and ABCG2
German scientists [15] have studied the effect of
three SNPs (rs1128503, rs2032582, rs1045642) in the
ABCB1 gene on the outcome of patients with GBM
treated with TMZ. Multivariate analysis showed that
the rs1128503 C;C (c.1236 T > C) is a prognostic
factor for the survival of patients treated with TMZ.
Carriers of C;T and T;T genotypes have 8% and 10%
2-year overall survival (OS) compared with 37%
survival in patients with C;C genotype ( p ¼ 0.02).
These data may indicate the role of rs1128503
(ABCB1) in the development of resistance of GBM
cells to TMZ. The effect of another SNP was identiﬁed in ABCG2 on disease-free and OS in patients
(n ¼ 580) with colorectal cancer treated with oxaliplatin therapy [15]. It was found that patients carrying ABCG2 rs2231142 C;C have a lower OS (odds
ratio [OR] ¼ 0.666, 95% conﬁdence interval [CI]:
0.527e0.843, p ¼ 0.001) than those carrying C;A and
A;A genotypes [16].
2.2. Drug resistance and proliferation
The proliferation of GBM cells is induced by
aberrant activation of EGF/EGFR, PDGF/PDGFRA
-B (platelet-derived growth factor/platelet-derived
growth factor receptor subunit A, -B), FGF2 (Fibroblast growth factor)/FGF2R, PI3K/AKT/NF-kB, and
STAT3 (signal transducer and activator of transcription 3) signaling pathways, which leads to the
development of MDR [17,18]. It is assumed that
PDGF/PDGFRA, -B and FGF2/FGF2R signaling are
linked with the MDR phenomenon. For example,
PI3K/AKT pathway increases GBM size [19]. In turn,
the expression TRF2 (telomere repeat-binding factor
2) stimulates the resistance to TMZ [20]. At the same
time, MGMT, ROBO1 (roundabout guidance receptor 1) proteins regulate the transcription factors
ZEB1 (zinc ﬁnger E-box binding homeobox 1) and
STAT3, which activate the proliferation and MDR
[21]. An activation of MGMT and resistance of
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[56]

[46]

rs699947
(c.-2578C > A)
rs1570360
(c.-1154G > A)
rs143119651 (c.7496A > G,
c.6248A > G, c.6815A > G)
rs11558961 (c.*28C > G, c.*28C > A)
6p21-p12, 6p21.1

1p36.22

17q21.31

VEGFA

MTOR

GFAP
(ALXDRD)

Mechanistic target of
rapamycin kinase
Glial ﬁbrillary acidic protein
G allele (OR ¼ 0.77, 95% CI: 0.61e0.97
C;G (OR ¼ 0.68, 95% CI: 0.49e0.95)
Note. SNP ¼ single-nucleotide polymorphism.

[45]

[38]
rs701848 (c.*1516 ¼ )
10q23.31
PTEN

A;A vs. A;C/C;C (HR ¼ 3.26, 1.29e8.22)*
(HR ¼ 7.02, 2.44e20.2)**
*association between SNP and PFS
**association between SNP and OS
C;C vs. C;T þ T;T (OR ¼ 1.169,
95% CI: 1.061e1.288;53)
C;C þ C;A (OR ¼ 2.56 (1.36e4.80)
C allele (OR ¼ 1.53 (1.14e2.03)
G;G (OR ¼ 1.53 (1.03e2.29),
G allele (OR ¼ 1.39 (1.01e1.91)
18q21.32
MC4R

Phosphatase and tensin
homolog
Vascular endothelial
growth factor A

[36]

[31]
10q26.3
MGMT

A;A vs. C;C, C;A (HR ¼ 2.876, HR ¼ 5.835)

rs1695 (c.313A > G)
rs730437
(c.748-49G > A)
rs1468727 (c.1631 þ 781C > T)
rs1625649
(c. 485C < A)
rs489693
(rs1673474)
11q13
7p11.2
GSTP1
EGFR

O-6-methylguanine-DNA
methyltransferase
Melanocortin 4 receptor

[26]
[29,30,40]

A allele vs G;G (OR ¼ 1.30, 95% CI: 0.91e1.87),
A;A vs. G;G (OR ¼ 1.76, 95% CI: 0.82e3.77)
A;A, A;G þ G;G, (HR ¼ 0.390 (0.196e0.775)
C;C, C allele (OR ¼ 1.32; 95% CI: 1.05e1.66)
C;C, C allele (OR ¼ 1.31, 95% CI: 1.04e1.65)
rs4444903 (c.61A > G)
4q25
EGF

Glutathione S-transferase pi-1
Epidermal growth factor receptor

References
Allele, genotype, model association with
SNP
Location
Gene

Table 1. Polymorphic Variants in Genes Associated with the Risk of Glioblastoma.

2.2.2. EGF, EGFR, MGMT, GSTP1, and IDH1/2
genes
An activation of signal transduction pathways induces the overexpression of the genes MGMT,
glutathione S-transferase p1 (GSTP1) which trigger
the proliferation and chemoresistance [26]. The
participation of these genes in GBM progression is
conﬁrmed by clinical genetic studies in which progression-free survival (PFS) and OS in patients with
rs16950 (c.313A > G) A;A genotype (GSTP1) treated
with TMZ were 10.5 months (95% CI: 6.7e14.4)
and 14.3 months (95% CI: 10.7e17.9), respectively
(Table 1) [26]. In addition, GBM progression is also
associated with the presence of the rs4444903 (c.61A
> G) A allele (OR ¼ 1.30, 95% CI: 0.91e1.87, p ¼
0.037) and A;A genotype (OR ¼ 1.76, 95% CI:
0.82e3.77, p ¼ 0.037) in the EGF gene compared with
G;G genotype. Carriers of genotypes A;A ( p ¼
0.042), A;G ( p ¼ 0.006), and A;A þ A;G ( p ¼ 0.008)
have a higher level of EGF than carriers of G;G
genotype (Table 1) [27]. Ampliﬁcation of EGFR is
associated with an increased risk of developing
GBM in patients receiving bevazizumab (OR ¼ 2.39,
95% CI: 1.36e4.18, p ¼ 0.007) and shorter OS ( p ¼
0.011) compared with individuals without ampliﬁcation [28]. The presence of rs730437 (OR ¼ 1.32;
95% CI: 1.05e1.66, p ¼ 0.016) and rs1468727 (OR ¼
1.31, 95% CI: 1.04e1.65, p ¼ 0.008) EGFR variants is
also associated with an increased risk of GBM
(Table 1) [29,30]. In another study, patients with
MGMT rs1625649 (c.485C < A) A;A had a higher
level of methylation of the gene promoter and lower

Gene product

2.2.1. MicroRNAs
The proliferation of gliomas is activated by miR-9,
miR-21, miR-130a, miR-130b, and miR-223 [22,23].
In turn, expression of miR-21 stimulates the passage
of the G0/G1 cell cycle and inhibition of the
apoptotic gene PDCD4 (programmed cell death 4),
which causes the resistance to doxorubicin [22].
MiR-223 activates GBM progression and its resistance to TMZ through the PAX6 (paired box 6)
regulation [23]. Drug resistance of GBM may be
associated with the inhibition of miR-218, miR-328,
and Let-7f (microRNA let7f) expression. Let-7f inhibits the expression of oncogenes via the Let-7f/
Pereostin pathway. This suppresses proliferation,
migration, and invasion of GBM [24,25].

Epidermal growth factor

U87MG and U251MG GBM cells to TMZ are also
observed during the formation of the complex of bcatenin with GSK-3b as a result of a decrease in the
level of b-catenin in the nucleus upon stimulation of
the transcription factor FOXO3a (forkhead box O3A)
[21].

[27]
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expression of the MGMT protein, which was associated with higher PFS than in patients with heterozygous (C;A) or wild-type (C;C) rs1625649
variants [31].
2.3. Drug resistance and recurrence
The recurrence of gliomas is accompanied by the
overexpression of EGFR and PDGFR, the activation
of G-protein-coupled receptor kinase 5 (GRK5), 44fold increase in the expression of SphK1-2 and
S1P1-3 compared with normal brain tissue [32].
Constitutive activation of EGFR stimulates hyperactivation of JAK2 (Janus kinase 2)/STAT3 and HGF/
c-MET, WNT1-3a/b-catenin signaling pathways
which activate the aggressiveness, the rate of proliferation of glioma cells, and activation of telomerase reverse transcriptase (TERT) [33,34]. This
correlation is conﬁrmed by the combined use of the
EGFR antagonist, Iressa, with the JAK2/STAT3 inhibitor, JSI-124, which causes the death of GBM cells
expressing EGFR [33]. EGFR/PTEN/AKT pathways
and TGF-b2 pathways also play a role in the malignancy of gliomas [35]. For example, an increase in
plasma TGF-b2 levels in patients with GBM is
associated with immunosuppression, loss of immune control over tumor progression, and poor
prognosis [35].
2.3.1. EGFR, TGFB1, and PTEN genes
It is known that melanocortins have anti-inﬂammatory and neuroprotective activity. Interestingly,
patients with rs489693 (A;A) in the melanocortin-4
receptor (MC4R) gene who receive chemotherapy
and radiotherapy have shorter PFS (2.99 vs. 10.8
months, p ¼ 0.009) and OS (10.8 vs. 29.5 months, p ¼
0.0001) than carriers of A;C and C;C genotypes
(Table 1) [36]. An international team of authors from
the United States, Canada, Germany, Great Britain,
and Israel [37], when carrying out genome-wide
association studies with the participation of 12,496
GBM patients and 18,190 healthy controls, established the correlation of EGFR rs723527 (c.88 þ
47814A > C) with progression of gliomas to GBM
(Table 1). However, according to the meta-analysis
[38], PTEN variant rs701848 (c.*1516 T > C) under the
recessive model (C;C vs. C;T þ T;T) is associated
with the development of glioma, stomach, breast,
and endometrial cancer in Asian populations.
2.4. Drug resistance and angiogenesis
During the formation of blood and lymphatic
vessels, the stroma and tumor cells exchange
secretory molecules. Vasculatory endothelial growth

factor receptor 1 (VEGFR1) is strongly expressed,
and vasculatory endothelial growth factor receptor2 and 3 (VEGFR2, VEGFR3) are weakly expressed
on GBM cells. The co-localization of MGMT with
VEGFR1 receptor activates the PI3K/AKT/mTOR
pathway, which enhances invasion, proliferation,
migration, and MDR of GBM cells [39]. Stimulation
of VEGF/VEGFR, PI3K/AKT/mTOR, and PDGFR
pathways in GB9B cells is associated with inhibition
of apoptosis and activation of caspases-3, 9, and
8. This is conﬁrmed by the use of selective inhibitors SU1498 for VEGF/VEGFR, BEZ235 for PI3K/
AKT/mTOR, and AG1433 for PDGFR, which
enhance caspase activation [40]. In GBM cells,
PDGF-C (platelet-derived growth factor C) and cMET kinases are coexpressed. The latter triggers the
HGF/c-MET/AKT pathway and enhances MDR [41].
The PI3K/AKT and Hedgehog pathways induce the
expression of FGF and its receptor (FGFR), which
promotes tumor angiogenesis and MDR [42].
Transactivation of DLL4 (delta-like canonical Notch
ligand 4)/NOTCH via FGF2/FGFR and EphB4 (EPH
receptor B4)/EprinB2 (ephrin B2) pathways stimulates GBM resistance to the VEGF inhibitor bevacizumab [43]. This pathway involves CDK5 (cyclindependent kinase 5), which activates the intracellular domain (NICD) of NOTCH (Neurogenic locus
notch homolog) and enhances the growth of
lymphatic vessels [44].
2.4.1. VEGFA and MTOR genes
VEGFA rs699947 C allele (OR ¼ 1.53, 95% CI:
1.14e2.03, p ¼ 0.004), G allele (OR ¼ 1.39, 95% CI:
1.01e1.91, p ¼ 0.04) and rs1570360 G;G genotype
(OR ¼ 1.53, 95% CI: 1.03e2.29, p ¼ 0.03) are associated with an increased risk of developing GBM
(Table 1) [45]. In turn, pathogenic MTOR variant
rs143119651 (c.7496A > G) may be present in GBM,
which reduces the binding of the mTOR protein to
its inhibitor Deptor, thereby increasing the resistance of the GBM to environmental deprivation
(Table 1) [46]. Since during angiogenesis the PI3K/
AKT/mTOR pathway is activated by the VEGFR1
receptor, in the presence of MTOR rs143119651,
GBM cells can acquire drug resistance.
2.5. Drug resistance and cell death
MDR of GBM is associated with inhibition of
apoptosis and JNK/SAPK (mitogen-activated protein kinase 9)/AP-1, NOTCH/HES1 (hairy and
enhancer of split-1) pathways, and regulation of
genes CJUN and CFOS [47]. In CD133þ-GBM cells,
the activation of heat shock protein 27 and heat
shock protein 72, caspases -9 and -3 are inhibited
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through the p38MAPK/MAPKAPK2 (mitogen-activated protein kinase-activated protein kinase 2)
pathway that indicates its participation in the
development of MDR [48,49]. Since TMZ is known
to stimulate the activation of caspase-8, AIF
(apoptosis-inducing factor), MAP3K14 (mitogenactivated protein kinase 14), and apoptosis in GBM
cells, at the same time, it inhibits the expression of
matrix metalloproteinase-9 (MMP-9) and matrix
metalloproteinase-2 (MMP-2), which indicates the
involvement of MMP-9 and MMP-2 in the development of MDR. The expression of p53 is inversely
correlated with MGMT in GBM cells. This indicates
the involvement of p53 in tumor sensitivity to TMZ,
which is conﬁrmed by the stimulatory effect of
carnosol (CAR) on p53, as a result of which the p53MDM2 complex dissociates, the p53 protein content
increases, and its synergistic effect with TMZ on
GBM cells is manifested [50].
2.5.1. MicroRNAs
MicroRNAs regulate the transcription of apoptotic
genes. For example, overexpression of miR-497 enhances glioma resistance to TMZ through suppression of the tumor suppressor PDCD4 [51].
Overexpression of miR-4284, activation of miR-183/
96/182 microRNA cluster, expression of AKTdependent genes FGF9 and FOXO1 (Forkhead box
O1) are observed in GBM stem cells. At the same
time, an inhibition of the microRNA cluster induces
ROS-dependent apoptosis via the p53 pathway [52].
MicroRNAs: miR-125b, miR-34a, miR-504, miR-3805P, miR-885-5P, miR-145, miR-34a for wild type p53,
and miR-21 regulate the expression of the p53 protein. MiR-21 also regulates other apoptotic proteins:
BCL-2 (B cell leukemia/lymphoma 2), caspase-9,
and BAX (BCL2-associated X, apoptosis regulator),
the latter is also regulated by miR-222 and miR-34a
[53].
2.5.2. Genes TP53 and GFAP
The presence of mutations in gene TP53 and
activation of BCL-2 lead to suppression of the activity of apoptotic proteins (caspase-3 and FADD
[Fas-associated death domain]), increased angiogenesis, and cell resistance to cisplatin [54]. For
example,
an
AAG
deletion
(c.594_597del)
(rs1555524949) of the TP53 gene, leading to a deletion of Glu199 in the p53 protein, is associated with
rapid tumor progression [55]. Interestingly, G allele
(OR ¼ 0.77, 95% CI: 0.61e0.97, p ¼ 0.042) and
rs11558961 C;G genotype (c.*28 ¼ ) of the GFAP gene
encoding the glial ﬁbrillar acidic protein (OR ¼ 0.68,
95% CI: 0.49e0.95, p ¼ 0.022) are associated with a
decrease in GBM chemoresistance (Table 1) [56].
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3. Conclusions
Chemoresistance is associated with aberrant effects of growth factors, cytokines, dysregulation of
their receptors’ activity, signaling transduction
pathways, the presence of mutations and SNPs in
oncogenes, and tumor suppressor genes involved in
proliferation, angiogenesis, cell metastasis, differentiation, apoptosis of GBM cells. The expression of
ABC transporters in GBM is regulated by miR-130a,
miR-200c microRNAs, transcription factors NF-kB,
AP-1, phosphatases, and kinases PTEN, PERK,
GSK-3b. With the proliferation and MDR of GBM
are associated signaling pathways: EGF/EGFR,
FGF2/FGF2R, PDGF/PDGFRA-B, STAT3, transcription factors ZEB1, ROBO1, FOXO3a. The presence of
polymorphisms rs1695 GSTP1, rs4444903 EGF,
rs730437, rs1468727, and rs723527 EGFR is associated
with the activation of cells proliferation of GBM.
Angiogenesis and MDR are stimulated by the
signaling pathways VEGF/VEGFR1-3, PI3K/AKT/
mTOR, and EGFR/JNK/ERK1/2. Polymorphisms
rs699947, rs1570360 (VEGFA), and rs143119651
(MTOR) are associated with both angiogenesis and
MDR of GBM cells. In the recurrence of GBM are
involved signaling pathways EGF/EGFR/JNK/
ERK1/2/AP-1, JAK2/STAT3, HGF/c-MET, WNT13a/b-catenin, EGFR/PTEN/AKT; genes EGFR,
TGFB1, and PTEN can be associated with the progression of GBM. Apoptosis and MDR are associated
with
JNK/SAPK/AP-1,
NOTCH/HES1,
p38MAPK/MAPKAPK2, and MAP3K14 signaling
pathways, proapoptotic proteins AIF, BCL-2,
CASP8, and p53, and genes CFOS and CJUN. Inhibition of apoptosis is associated with rs11558961
(GFAP) polymorphism. Thus, the aforementioned
factors can be considered as targets in the development of new targeted antitumor biological and
chemotherapy drugs.
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